Document Detail


Clevidipine : a state-of-the-art antihypertensive drug under the scope.
MedLine Citation:
PMID:  22251017     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Clevidipine butyrate is the first intravenous antihypertensive drug to be approved by the FDA over the last decade. This medication is approved for use in the USA, Australia and New Zealand, but is still pending for approval in Europe. It is a new agent that might change the current management for severe acute hypertension in the critical care, emergency and perioperative areas.
AREAS COVERED: This systematic review summarizes the pharmacological and clinical characteristics of this third-generation dihydropyridine intravenous calcium channel blocker, and was done using the literature available from the first publication in 1999 up until now, including the pivotal trials that led to its approval.
EXPERT OPINION: This agent is arterially selective, has an ultrashort half-life, with no CYP-mediated interactions with other medications and is easily titratable. These characteristics place it in a unique category compared with other commonly used antihypertensives. Clevidipine butyrate reaches target systolic blood pressure in more than 90% of patients, within 30 min. It has a low incidence of adverse reactions and is generally well tolerated. The main goal of this review is to provide healthcare providers with a comprehensive appraisal of this promising medication.
Authors:
Ilse M Espina; Joseph Varon
Related Documents :
22114347 - Medical humanities as expressive of western culture.
22225447 - Influence of study approaches on academic outcomes during pre-clinical medical education.
23343447 - The pharmacokinetics of long-acting antipsychotic medications.
22189887 - Perspective: partnering for medical education in sub-saharan africa: seeking the eviden...
20158317 - The association between achieving low-density lipoprotein cholesterol (ldl-c) goal and ...
24722537 - Patient- and clinic visit-related factors associated with potentially inappropriate med...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-01-18
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-25     Completed Date:  2012-06-06     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  387-93     Citation Subset:  IM    
Affiliation:
Dorrington Medical Associates , 2219 Dorrington Street, Houston, Texas 77030 , USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antihypertensive Agents / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Blood Pressure / drug effects
Calcium Channel Blockers / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Humans
Hypertension / drug therapy*,  physiopathology
Infusions, Intravenous
Pyridines / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Pyridines; 19O2GP3B7Q/clevidipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aortic Interruption Presenting with Recurrent Ischemic Strokes in an Adult.
Next Document:  Free-living and aggregate-associated Planctomycetes in the Black Sea.